Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral nerve stimulation registry for intractable migraine headache (RELIEF): a real-life perspective on the utility of occipital nerve stimulation for chronic migraine.

Acta neurochirurgica·2020
Same author

Predicting low back pain outcome following rehabilitation for low back pain.

Journal of back and musculoskeletal rehabilitation·2014
Same author

Peripheral occipital nerve stimulation to treat chronic refractory migraine.

British journal of hospital medicine (London, England : 2005)·2013
Same author

Predicting erectile function outcome in men after radical prostatectomy for prostate cancer.

BJU international·2011
Same author

Job strain related to cognitive failure in naval personnel.

Ergonomics·2010
Same author

Resuscitation decisions among hospital physicians and intensivists.

Clinical medicine (London, England)·2009

Related Experiment Video

Updated: Jul 11, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Patient preference for triptan formulations: a prospective study with zolmitriptan.

Andrew Dowson1, Michael Bundy, Rebecca Salt

  • 1King's Headache Service, King's College Hospital, London, UK.

Headache
|September 22, 2007
PubMed
Summary

Patient preferences for zolmitriptan formulations shifted from conventional tablets to ODT and nasal spray over time. Convenience drove ODT preference, while speed and efficacy favored nasal spray for migraine relief.

Related Experiment Videos

Last Updated: Jul 11, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Area of Science:

  • Migraine treatment and management
  • Pharmacological interventions for neurological disorders
  • Patient-centered care in primary health settings

Background:

  • Migraine patients exhibit distinct preferences for specific triptan formulations, despite minimal efficacy differences.
  • Understanding patient profiles and motivations behind formulation choices remains limited.

Purpose of the Study:

  • To investigate patient preferences for three zolmitriptan formulations (conventional tablets, ODT, nasal spray) in a primary care setting.
  • To explore the reasons behind patient formulation preferences for migraine treatment.
  • To assess the impact of formulation preference on headache-related disability.

Main Methods:

  • A prospective, randomized, open-label, crossover, longitudinal study involving migraine patients.
  • Patients used zolmitriptan 2.5-mg film-coated tablets, 2.5-mg Orally Disintegrating Tablets (ODT), and 5-mg nasal spray sequentially.
  • Patient preferences, reasons for preference, and Migraine Disability Assessment (MIDAS) scores were recorded over a 12-month period.

Main Results:

  • Initial preference for conventional tablets shifted significantly, with 46.9% favoring ODT and 43.8% favoring nasal spray after 4 months.
  • Key drivers for ODT preference included convenience and speed of onset; nasal spray preference was driven by speed and overall efficacy.
  • Significant reductions in MIDAS scores were observed, indicating improved headache-related disability. Zolmitriptan was well-tolerated across formulations.

Conclusions:

  • Patient experience with newer zolmitriptan formulations, particularly ODT and nasal spray, led to a change in preference from conventional tablets.
  • Convenience was the primary factor for ODT preference, whereas speed and efficacy influenced the choice of nasal spray.
  • Naturalistic, longitudinal studies in primary care can effectively capture patient experiences and preferences in migraine management.